Empagliflozin/linagliptin/metformin explained

Type:combo
Component1:Empagliflozin
Class1:SGLT2 inhibitor
Component2:Linagliptin
Class2:DPP-4 inhibitor
Component3:Metformin
Class3:Anti-diabetic biguanide
Tradename:Trijardy XR
Dailymedid:Empagliflozin linagliptin metformin
Routes Of Administration:By mouth
Atc Prefix:A10
Atc Suffix:BD27
Legal Us:Rx-only
Legal Us Comment:[1]
Kegg:D11856

Empagliflozin/linagliptin/metformin, sold under the brand name Trijardy XR, is a fixed-dose combination medication used for the treatment of type 2 diabetes.[2] It is a combination of empagliflozin, linagliptin, and metformin. Empagliflozin/linagliptin/metformin was approved for use in the United States in January 2020.[3] [4]

__TOC__

Adverse effects

To reduce the risk of developing ketoacidosis (a serious condition where the body produces high levels of blood acids called ketones) after surgery, the FDA has approved changes to the prescribing information for SGLT2 inhibitor diabetes medications, recommending they be temporarily stopped before scheduled surgery. Empagliflozin should each be stopped at least three days before scheduled surgery.[5]

Symptoms of ketoacidosis include nausea, vomiting, abdominal pain, tiredness, and trouble breathing.

History

The combination preparation was developed and marketed by Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.[6] [7]

Notes and References

  1. Web site: Trijardy XR- empagliflozin, linagliptin, metformin hydrochloride tablet, extended release . live . https://web.archive.org/web/20211225053438/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=71873567-9594-452a-bb92-34a129adecac . 25 December 2021 . 24 December 2021 . DailyMed.
  2. Kim ES, Deeks ED . September 2015 . Empagliflozin/Linagliptin: A Review in Type 2 Diabetes . Drugs . 75 . 13 . 1547–57 . 10.1007/s40265-015-0457-z . 26323340 . 27675087.
  3. Web site: Trijardy XR: FDA-Approved Drugs . live . https://web.archive.org/web/20200523144822/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212614 . 23 May 2020 . 11 February 2020 . U.S. Food and Drug Administration (FDA).
  4. US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes . 27 January 2020 . Eli Lilly and Company . PR Newswire . 10 February 2020 . live . https://web.archive.org/web/20200213020137/https://www.prnewswire.com/news-releases/us-fda-approves-only-triple-combination-tablet-with-jardiance-for-adults-with-type-2-diabetes-300993928.html . 13 February 2020.
  5. Web site: 19 March 2020 . FDA revises labels of SGLT2 inhibitors for diabetes to include warning . live . https://web.archive.org/web/20200607011955/https://www.fda.gov/drugs/drug-safety-and-availability/fda-revises-labels-sglt2-inhibitors-diabetes-include-warnings-about-too-much-acid-blood-and-serious . 7 June 2020 . 6 June 2020 . U.S. Food and Drug Administration.
  6. US FDA approves only triple-combination tablet with Jardiance for adults with type 2 diabetes . 27 January 2020 . Boehringer Ingelheim . 10 February 2020 . live . https://web.archive.org/web/20200213014522/https://www.boehringer-ingelheim.us/press-release/us-fda-approves-only-triple-combination-tablet-jardiance-adults-type-2-diabetes . 13 February 2020.
  7. Web site: Trijardy XR (empagliflozin, linagliptin, and metformin hydrochloride extended-release tablets), for oral use . live . https://web.archive.org/web/20200213020152/https://docs.boehringer-ingelheim.com/Prescribing . 13 February 2020 . 10 February 2020 . Boehringer Ingelheim.

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Empagliflozin/linagliptin/metformin".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2025, A B Cryer, All Rights Reserved. Cookie policy.